Viracta Therapeutics to Present at Key Investment Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a prominent name in precision oncology, is preparing for a significant presentation at the H.C. Wainwright 26th Annual Global Investment Conference. Scheduled for an important date in New York City, this event will provide Viracta with an excellent opportunity to highlight its innovations and progress in cancer treatment.
Highlights of the Presentation
Mark Rothera, the President and Chief Executive Officer of Viracta Therapeutics, will present the company's vision and share updates on their clinical trials. Attendees can expect insights into their advanced treatment approaches focused on targeted cancer therapies, especially those linked to viral infections.
About Viracta Therapeutics
Viracta Therapeutics is dedicated to addressing virus-associated cancers, working tirelessly to advance treatment options for these complex conditions. Their leading product candidate, Nana-val, is an innovative combination therapy that merges the investigational drug nanatinostat with the antiviral medication valganciclovir.
Nana-val and Its Clinical Trials
The Nana-val therapy is currently being rigorously tested in several clinical trials. A key study, NAVAL-1, is a potentially groundbreaking Phase 2 trial assessing its effectiveness against various subtypes of relapsed or refractory Epstein-Barr virus-positive (EBV+) lymphoma. This global initiative underscores Viracta's commitment to meeting unmet medical needs in oncology.
Current Research and Future Directions
Beyond its lymphoma trials, Viracta is investigating new treatment options for recurrent or metastatic EBV+ nasopharyngeal carcinoma and advanced solid tumors. The company’s innovative “Kick and Kill” strategy aims to leverage the immune system to tackle other virus-related cancers, potentially revolutionizing treatment methodologies.
Engaging with Investors
Viracta places a strong emphasis on investor relations, inviting stakeholders to accompany them on their journey through the presentation and beyond. Interested individuals can access a live webcast of the event on their official website, which will remain available for viewing for 90 days after the event.
Contact Information
For any inquiries related to investments or corporate information, please reach out to Michael Faerm, Chief Financial Officer at Viracta Therapeutics. He is available via email for any investor relations questions.
Frequently Asked Questions
What is the focus of Viracta Therapeutics?
Viracta Therapeutics focuses on precision oncology treatments, particularly for cancers associated with viruses.
Who will present at the H.C. Wainwright conference?
Mark Rothera, the CEO of Viracta, will be presenting at the conference.
What is Nana-val?
Nana-val is an oral combination therapy being researched for its effectiveness against cancers related to EBV.
Where can I find more information about Viracta?
More details can be found on the official Viracta Therapeutics website.
How can I contact Viracta for investor inquiries?
Investors can contact Michael Faerm via email for any inquiries related to investor relations.